Abbott Laboratories (ABL) AI Stock Analysis

Abbott Laboratories

(XETRA:ABL)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Diversified Healthcare PortfolioAbbott’s presence across four healthcare segments diversifies revenue sources and reduces reliance on any single product category. Recurring demand for diagnostics consumables, diabetes sensors, nutrition products, and medicines supports a broad, durable operating base over the next several quarters.

Negative Factors

Higher LeverageThe sharp increase in debt reduces financial flexibility relative to prior periods and makes Abbott more dependent on sustained operating cash generation. Higher leverage can constrain capital allocation and increase sensitivity to refinancing costs or weaker operating conditions over the medium term.

Abbott Laboratories (ABL) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 183.77B
Dividend Yield: 2.29%
Average Volume (3M): 719
Price to Earnings (P/E): 39.3
Beta (1Y): 0.30
Revenue Growth: 4.64%
EPS Growth: ―
Country: Germany
Employees: 115,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Abbott Laboratories Business Overview & Revenue Model

Company Description

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four...

Abbott Laboratories Earnings Call Summary

Earnings Call Date:Oct 20, 2026(Q3-2026)|% Change Since:3.70%|Next Earnings Date:Jan 26, 2027

Earnings Call SentimentPositive

The call was strongly constructive: Abbott delivered 7% sales growth, 9% EPS growth, margin expansion, broad segment growth, multiple product approvals and launches, and announced a strategic nutrition separation intended to improve the growth and margin profile of the remaining company. The main negatives were a reduced full-year revenue outlook, short-term electrophysiology and diabetes headwinds, cybersecurity-related disruption in cancer diagnostics, foreign-exchange pressure, and uncertainty around 2027 guidance and CMS reimbursement timing. Highlights significantly outweighed the lowlights.

Positive Updates

Third-Quarter Revenue and EPS Growth Accelerated

Third-quarter sales grew 7% and earnings per share grew 9%, representing an acceleration in both the top and bottom lines compared with the first half of the year. Adjusted EPS was $1.42, in line with guidance and the consensus estimate.

Negative Updates

Foreign Exchange Was a Sales Headwind

Foreign exchange had an unfavorable year-over-year impact of 0.4% on third-quarter sales. Based on current rates, Abbott expects exchange to have a negative impact of approximately 1% on fourth-quarter sales.

Company Guidance

Abbott anticipates completing the nutrition separation by the end of next year, subject to the required approvals; following separation, sales growth is expected to accelerate by 50 to 100 basis points, gross margin as a percent of sales to increase by more than 200 basis points, and operating margin as a percent of sales to increase by approximately 100 basis points. For the fourth quarter, exchange is expected to have a negative impact of approximately 1% on sales, and adjusted earnings per share is forecast at $1.62 to $1.67; full-year sales growth around 6% implies just north of 8% in the fourth quarter. EP growth is expected to be around 20% in Q4 versus around 25% previously, while diabetes growth is expected to be in the low to mid-single range for Q4 and probably for the next few quarters. For 2027, sales are expected to be, as Abbott comes out of the gate, pretty similar to this year, with EPS growth, gross margin expansion, and earnings growth expected, but specific guidance ranges will be provided in January.

Abbott Laboratories Risk Analysis

Abbott Laboratories disclosed 19 risk factors in its most recent earnings report. Abbott Laboratories reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Abbott Laboratories Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:ABL against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EW	81Outperform	$53.03B	52.88	9.69%	―	14.55%	15.09%
MDT	74Outperform	$123.49B	23.60	10.60%	2.96%	9.77%	12.28%
DXCM	73Outperform	$30.69B	31.77	36.50%	―	13.03%	40.88%
GEHC	71Outperform	$34.62B	19.84	16.13%	0.19%	6.87%	-2.26%
BSX	68Neutral	$60.84B	17.71	14.18%	―	8.88%	25.77%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:ABL and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:ABL	Abbott Laboratories	95.24	-8.88	-8.53%
BSX	Boston Scientific	41.98	-56.61	-57.42%
DXCM	Dexcom	82.29	21.86	36.17%
EW	Edwards Lifesciences Corp.	92.01	8.94	10.76%
MDT	Medtronic	96.54	9.23	10.58%
GEHC	Ge Healthcare Technologies Inc.	76.57	2.25	3.03%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Abbott Laboratories AI Stock Analysis